[A clinical evaluation of the CA 72-4 serum level as a possible tumor marker].
The level of CA 72-4 in serum has been measured in various diseases by an immunoradiometric assay using CA 72-4 RIA Kit for an evaluation of its clinical significance as a possible tumor marker. CA 72-4 showed a high positive rate in patients with ovarian and bile duct cancers. In contrast, the false positive rate was low in benign gynecological and digestive diseases. Serum CA 72-4 was found to be increased in patients with a mucinous cystadenocarcinoma and in other histological types in the early stages of an ovarian cancer. Further, the serum CA 72-4 level changed in parallel with the clinical course of the ovarian cancer. Therefore, our results suggest that measurement of CA 72-4 be combined with measurement of CA 125, so as to provide a better sensitivity and specificity in monitoring an ovarian cancer.
Jibiki
K
K
Radioassay Center, Tokyo Women's Med. College.
Takeda
M
M
Abe
H
H
Ito
M
M
Odagiri
E
E
Demura
R
R
Demura
H
H
Takizawa
K
K
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis; D008297:Male; D010051:Ovarian Neoplasms / Q000175:diagnosis*; D013274:Stomach Neoplasms / Q000175:diagnosis*; D014594:Uterine Neoplasms / Q000175:diagnosis
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor